In this edition, we highlight our two latest pieces. The first examines the evolution of immune checkpoint inhibitors - their progress, limitations, and emerging targets such as LAG-3 and TIGIT. The second explores the challenges of immune-excluded and immune-deserted tumor microenvironments that characterize 'cold' tumors and evaluates the potential of antifibrotic combination strategies to enhance immunotherapy efficacy.
Alacrita Consulting
生物技术研究
Cambridge，Massachusetts 4,631 位关注者
Industry-leading consultants with the full-range of specialist expertise needed to develop & commercialize drug products
关于我们
Alacrita is a pharma and biotech consulting firm whose value to clients is founded on the first-hand experience of its subject-matter experts. Consultants who have spent their careers discovering, developing, manufacturing and commercializing drug products. Our core team leverages a purpose-built network of over 250 such experts who are brought into project teams when specialist expertise is needed. This allows us to provide clients with precisely relevant support on a range of R&D and business issues. We do this while also offering the speed and flexibility expected from a professional life science consulting firm. Our expert teams are ready to support you through every step of the pharmaceutical product development process, leveraging our scientific, clinical and commercial expertise to help you maximize value at each stage. We offer substantial expertise & experience in the following areas: Product Development Services: - Clinical Development - CMC & Supply Chain - Interim Chief Medical Officer Support - Preclinical Strategy & Execution - Regulatory Affairs - Research & IP Evaluation Strategy & Commercialization Services: - Business Plans & Fundraising Support - Opportunity Mapping - New Product Planning - Launch Planning Business Development Services: - Asset Scouting - Due Diligence - Licensing, Partnering & Dealmaking - Pharma & Biotech Valuations Visit www.alacrita.com to learn more.
- 网站
-
https://www.alacrita.com
Alacrita Consulting的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Cambridge，Massachusetts
- 类型
- 私人持股
- 创立
- 2009
- 领域
- Functional Support、Due Diligence、Clinical Development Strategy, Planning & Hands-On Support、Asset Scouting、Licensing & Partnering Guidance, Strategy & Preparation、TTO Program Prioritization、Valuations、Opportunity Mapping、Target Product Profiles和New Product Planning
地点
Alacrita Consulting员工
动态
-
Compounding pharmacies seem to be carving out an increasingly larger role in the industry—filling drug shortages, personalizing treatments, and challenging traditional pharma models. As their influence grows, so do the questions: Are they allies in patient care or a disruptive force to commercialization and pricing strategies? Read more: https://lnkd.in/eszUKgfb
-
-
While cancer immunotherapy has revolutionized the landscape of treatment, significant challenges remain, particularly in addressing the immune-excluded and immune-deserted tumor microenvironments (TME). But could combination strategies involving antifibrotics be the key to breaking through the barrier??Learn more: https://lnkd.in/e9E6E6gY
-
-
As we move into the new year, we hope the insights and articles we've shared?throughout 2024 have provided valuable perspective and guidance?helpful for?navigating the opportunities and challenges to come. In this edition, you'll find our top publications from the year. Happy holidays from all of us at Alacrita!
-
Aggregate deals and financing in cell and gene therapy has dropped by 62% since the peak in 2021. In itself, that's not surprising as during the coronavirus pandemic when lockdowns and travel restrictions freed up so much time that the rate of dealmaking and investing was doubled - maybe fuelled by the extra available energy released by not having to endure the stress of travel or just simply boredom of WFH?. But there is a general loss of appetite in the C> field given that commercial returns have (of course) not lived up to the hype. However, underlying science continues to forge ahead and many suspect there will be a revival in the medium term.
-
Biotech startups often need experienced medical leaders at times when bringing on full-time hires simply isn't practical. Fractional CMOs offer a solution: high-level expertise on a flexible basis. These seasoned professionals?bring invaluable experience to clinical trials, regulatory affairs, and investor relations, allowing startups to navigate key growth phases without the cost of a full-time executive. Learn more: https://lnkd.in/eRahH39Z
-
-
Revitalized by biological discoveries and combined with strong pipelines, a plethora of new targets, and plenty of unmet therapeutic needs, the stage is set for a new phase of growth in dermatology drug development. Learn more: https://lnkd.in/epzHn3sG
-
-
Alacrita is pleased to announce that Michael Lombardo, PharmD, PhD, has joined our consulting team in the Cambridge, MA office. Michael has extensive experience with drug discovery, biomarker development, and small molecule therapeutics, along with expertise in oncology and infectious diseases spanning the full drug development lifecycle. Learn more: https://lnkd.in/e5XPTpU9
-
-
Longer lives are great,?but how about healthier ones??As lifespans increase, so can the gap between lifespan and healthspan, simply leading to more years spent with chronic disease. Our latest paper explores the senotherapy field and some of the current advances that hope to change that.?Learn more: https://lnkd.in/e3Uy_nJr?
-
-
A decade at Alacrita Consulting